Coartem^®: a decade of patient-centric malaria management

References

• WHO. World Malaria Report. WHO, Geneva, Switzerland (2011).
   Google Scholar
• Otten M, Aregawi M, Were W et al. Initial evidence of reduction of malaria cases and deaths in Rwanda and Ethiopia due to rapid scale-up of malaria prevention and treatment. Malar. J.8, 14 (2009).
   PubMed Web of Science ®Google Scholar
• Bhattarai A, Ali AS, Kachur SP et al. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med.4(11), E309 (2007).
   PubMed Web of Science ®Google Scholar
• WHO. Guidelines for the Treatment of Malaria (2nd Edition). WHO, Geneva, Switzerland (2010).
   Google Scholar
• WHO. WHO Model List of Essential Medicines. WHO, Geneva, Switzerland (2010).
   Google Scholar
• WHO. WHO Model List of Essential Medicines for Children. WHO, Geneva, Switzerland (2010).
   Google Scholar
• Tshefu AK, Gaye O, Kayentao K et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine–artesunate compared with artemether–lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet375(9724), 1457–1467 (2010).
   PubMed Web of Science ®Google Scholar
• Nambozi M, van Geertruyden JP, Hachizovu S et al. Safety and efficacy of dihydroartemisinin–piperaquine versus artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malar. J.10, 50 (2011).
   PubMedGoogle Scholar
• White NJ, van VM, Ezzet F. Clinical pharmacokinetics and pharmacodynamics of artemether–lumefantrine. Clin. Pharmacokinet.37(2), 105–125 (1999).
   PubMed Web of Science ®Google Scholar
• Kokwaro G, Mwai L, Nzila A. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Expert Opin. Pharmacother.8(1), 75–94 (2007).
   PubMed Web of Science ®Google Scholar
• Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob. Agents Chemother.44(3), 697–704 (2000).
   PubMed Web of Science ®Google Scholar
• Ashley EA, Stepniewska K, Lindegardh N et al. Pharmacokinetic study of artemether–lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. Trop. Med. Int. Health12(2), 201–208 (2007).
   PubMed Web of Science ®Google Scholar
• Lefèvre G, Carpenter P, Souppart C et al. Interaction trial between artemether–lumefantrine (Riamet) and quinine in healthy subjects. J. Clin. Pharmacol.42(10), 1147–1158 (2002).
   PubMed Web of Science ®Google Scholar
• Djimde AA, Tekete M, Abdulla S et al. Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether–lumefantrine in African children with uncomplicated Plasmodium falciparum malaria. Antimicrob. Agents Chemother.55(9), 3994–3999 (2011).
   PubMed Web of Science ®Google Scholar
• Coartem ® international package leaflet. Novartis Pharma AG, Basel, Switzerland (2009).
   Google Scholar
• Evaluation of a new chemical entity, CGP56695, as an inhibitor of human P450 enzymes. Report DMPK (CH) 1997/073. Drug metabolism & pharmacokinetics. Novartis Pharma AG, Basel, Switzerland (1997).
   Google Scholar
• Lefèvre G, Thomsen MS. Clinical pharmacokinetics of artemether and lumefantrine (Riamet®). Clin. Drug Invest.18, 467–480 (1999).
   Web of Science ®Google Scholar
• Bindschedler M, Lefevre G, Ezzet F, Schaeffer N, Meyer I, Thomsen MS. Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers. Eur. J. Clin. Pharmacol.56(5), 375–381 (2000).
   PubMed Web of Science ®Google Scholar
• Lefèvre G, Bindschedler M, Ezzet F, Schaeffer N, Meyer I, Thomsen MS. Pharmacokinetic interaction trial between co-artemether and mefloquine. Eur. J. Pharm. Sci.10(2), 141–151 (2000).
   PubMed Web of Science ®Google Scholar
• Lefèvre G, Carpenter P, Souppart C, Schmidli H, McClean M, Stypinski D. Pharmacokinetics and electrocardiographic pharmacodynamics of artemether–lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. Br. J. Clin. Pharmacol.54(5), 485–492 (2002).
   PubMed Web of Science ®Google Scholar
• van Agtmael MA, Gupta V, van der Wosten TH, Rutten JP, van Boxtel CJ. Grapefruit juice increases the bioavailability of artemether. Eur. J. Clin. Pharmacol.55(5), 405–410 (1999).
   PubMed Web of Science ®Google Scholar
• German P, Parikh S, Lawrence J et al. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J. Acquir. Immune Defic. Syndr.51(4), 424–429 (2009).
   PubMed Web of Science ®Google Scholar
• Kredo T, Mauff K, Van der Walt JS et al. Interaction between artemether–lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. Antimicrob. Agents Chemother.55(12), 5616–5623 (2011).
   PubMed Web of Science ®Google Scholar
• Hatz C, Soto J, Nothdurft HD et al. Treatment of acute uncomplicated falciparum malaria with artemether–lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. Am. J. Trop. Med. Hyg.78(2), 241–247 (2008).
   PubMed Web of Science ®Google Scholar
• van Vugt M, Wilairatana P, Gemperli B et al. Efficacy of six doses of artemether–lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg.60(6), 936–942 (1999).
   PubMed Web of Science ®Google Scholar
• van Vugt M, Looareesuwan S, Wilairatana P et al. Artemether–lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans. R. Soc. Trop. Med. Hyg.94(5), 545–548 (2000).
   PubMed Web of Science ®Google Scholar
• Lefèvre G, Looareesuwan S, Treeprasertsuk S et al. A clinical and pharmacokinetic trial of six doses of artemether–lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am. J. Trop. Med. Hyg.64(5–6), 247–256 (2001).
   PubMed Web of Science ®Google Scholar
• Abdulla S, Sagara I, Borrmann S et al. Efficacy and safety of artemether–lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet372(9652), 1819–1827 (2008).
   PubMed Web of Science ®Google Scholar
• Makanga M, Bassat Q, Falade CO et al. Efficacy and safety of artemether–lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis. Am. J. Trop. Med. Hyg.85(5), 793–804 (2011).
   PubMed Web of Science ®Google Scholar
• Falade C, Makanga M, Premji Z, Ortmann CE, Stockmeyer M, De Palacios PI. Efficacy and safety of artemether–lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans. R. Soc. Trop. Med. Hyg.99(6), 459–467 (2005).
   PubMed Web of Science ®Google Scholar
• Arinaitwe E, Sandison TG, Wanzira H et al. Artemether–lumefantrine versus dihydroartemisinin–piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin. Infect. Dis.49(11), 1629–1637 (2009).
   PubMed Web of Science ®Google Scholar
• Makanga M, Krudsood S. The clinical efficacy of artemether/lumefantrine (Coartem). Malar. J.8(Suppl. 1), S5 (2009).
   PubMedGoogle Scholar
• Achan J, Tibenderana JK, Kyabayinze D et al. Effectiveness of quinine versus artemether–lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ339, B2763 (2009).
   PubMedGoogle Scholar
• Elamin SB, Awad AI, Eltayeb IB et al. Descriptive study on the efficacy of artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Sudan. Eur. J. Clin. Pharmacol.66(3), 231–237 (2010).
   PubMed Web of Science ®Google Scholar
• Mens PF, Sawa P, van Amsterdam SM et al. A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether–lumefantrine versus dihydroartemisinin–piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Malar. J.7, 237 (2008).
   PubMedGoogle Scholar
• Sykes A, Hendriksen I, Mtove G et al. Azithromycin plus artesunate versus artemether–lumefantrine for treatment of uncomplicated malaria in Tanzanian children: a randomized, controlled trial. Clin. Infect. Dis.49(8), 1195–1201 (2009).
   PubMed Web of Science ®Google Scholar
• Bassat Q, Mulenga M, Tinto H et al. Dihydroartemisinin–piperaquine and artemether–lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One4(11), E7871 (2009).
   PubMed Web of Science ®Google Scholar
• Bell DJ, Wootton D, Mukaka M et al. Measurement of adherence, drug concentrations and the effectiveness of artemether–lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. Malar. J.8, 204 (2009).
   PubMedGoogle Scholar
• Ajayi IO, Browne EN, Bateganya F et al. Effectiveness of artemisinin-based combination therapy used in the context of home management of malaria: a report from three study sites in sub-Saharan Africa. Malar. J.7, 190 (2008).
   PubMedGoogle Scholar
• Faucher JF, Aubouy A, Adeothy A et al. Comparison of sulfadoxine–pyrimethamine, unsupervised artemether–lumefantrine, and unsupervised artesunate–amodiaquine fixed-dose formulation for uncomplicated Plasmodium falciparum malaria in Benin: a randomized effectiveness noninferiority trial. J. Infect. Dis.200(1), 57–65 (2009).
   PubMed Web of Science ®Google Scholar
• Faye B, Offianan AT, Ndiaye JL et al. Efficacy and tolerability of artesunate–amodiaquine (Camoquin plus) versus artemether–lumefantrine (Coartem) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast. Trop. Med. Int. Health15(5), 608–613 (2010).
   PubMed Web of Science ®Google Scholar
• Faye B, Ndiaye JL, Tine R et al. A randomized trial of artesunate mefloquine versus artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Senegalese children. Am. J. Trop. Med. Hyg.82(1), 140–144 (2010).
   PubMed Web of Science ®Google Scholar
• Kobbe R, Klein P, Adjei S et al. A randomized trial on effectiveness of artemether–lumefantrine versus artesunate plus amodiaquine for unsupervised treatment of uncomplicated Plasmodium falciparum malaria in Ghanaian children. Malar. J.7, 261 (2008).
   PubMed Web of Science ®Google Scholar
• Ndiaye JL, Randrianarivelojosia M, Sagara I et al. Randomized, multicentre assessment of the efficacy and safety of ASAQ – a fixed-dose artesunate–amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. Malar. J.8, 125 (2009).
   PubMed Web of Science ®Google Scholar
• Okafor HU, Shu EN, Oguonu T. Therapeutic efficacy and effect on gametocyte carriage of an artemisinin and a non-based combination treatment in children with uncomplicated P. falciparum malaria, living in an area with high-level chloroquine resistance. J. Trop. Pediatr.56(6), 398–406 (2010).
   PubMed Web of Science ®Google Scholar
• Sagara I, Diallo A, Kone M et al. A randomized trial of artesunate–mefloquine versus artemether–lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. Am. J. Trop. Med. Hyg.79(5), 655–661 (2008).
   PubMedGoogle Scholar
• Sagara I, Rulisa S, Mbacham W et al. Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether–lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial. Malar. J.8, 63 (2009).
   PubMedGoogle Scholar
• Toure OA, Penali LK, Yapi JD et al. A comparative, randomized clinical trial of artemisinin/naphtoquine twice daily one day versus artemether/lumefantrine six doses regimen in children and adults with uncomplicated falciparum malaria in Cote d’Ivoire. Malar. J.8, 148 (2009).
   PubMedGoogle Scholar
• Karunajeewa HA, Mueller I, Senn M et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N. Engl. J. Med.359(24), 2545–2557 (2008).
   PubMed Web of Science ®Google Scholar
• Valecha N, Srivastava P, Mohanty SS et al. Therapeutic efficacy of artemether–lumefantrine in uncomplicated falciparum malaria in India. Malar. J.8, 107 (2009).
   PubMedGoogle Scholar
• Adam I, Salah MT, Eltahir HG, Elhassan AH, Elmardi KA, Malik EM. Dihydroartemisinin–piperaquine versus artemether–lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan. Ann. Trop. Med. Parasitol.104(4), 319–326 (2010).
   PubMed Web of Science ®Google Scholar
• Ndiaye JL, Faye B, Gueye A et al. Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial. Malar. J.10, 237 (2011).
   PubMedGoogle Scholar
• Yavo W, Faye B, Kuete T et al. Multicentric assessment of the efficacy and tolerability of dihydroartemisinin–piperaquine compared to artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Malar. J.10, 198 (2011).
   PubMed Web of Science ®Google Scholar
• Menan H, Faye O, Same-Ekobo A et al. Comparative study of the efficacy and tolerability of dihydroartemisinin–piperaquine-trimethoprim versus artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroon, Ivory Coast and Senegal. Malar. J.10, 185 (2011).
   PubMedGoogle Scholar
• Dunyo S, Sirugo G, Sesay S et al. Randomized trial of safety and effectiveness of chlorproguanil-dapsone and lumefantrine-artemether for uncomplicated malaria in children in the Gambia. PLoS One6(6), E17371 (2011).
   PubMedGoogle Scholar
• Toure OA, Kouame MG, Didier YJ et al. Artesunate/mefloquine paediatric formulation vs. artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum in Anonkoua koute, Cote d’Ivoire. Trop. Med. Int. Health16(3), 290–297 (2011).
   PubMed Web of Science ®Google Scholar
• Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst. Rev.3, CD007483 (2009).
   Google Scholar
• A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med.8(11), E1001119 (2011).
   PubMed Web of Science ®Google Scholar
• Ouedraogo AL, Bousema T, Schneider P et al. Substantial contribution of submicroscopical Plasmodium falciparum gametocyte carriage to the infectious reservoir in an area of seasonal transmission. PLoS One4(12), E8410 (2009).
   PubMedGoogle Scholar
• Borrmann S, Sallas WM, Machevo S et al. The effect of food consumption on lumefantrine bioavailability in African children receiving artemether–lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria. Trop. Med. Int. Health15(4), 434–441 (2010).
   PubMed Web of Science ®Google Scholar
• Premji ZG, Abdulla S, Ogutu B et al. The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether–lumefantrine: a review of the evidence. Malar. J.7, 244 (2008).
   PubMedGoogle Scholar
• Toovey S, Jamieson A. Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans. R. Soc. Trop. Med. Hyg.98(5), 261–267 (2004).
   PubMed Web of Science ®Google Scholar
• Gurkov R, Eshetu T, Miranda IB et al. Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial. Malar. J.7, 179 (2008).
   PubMed Web of Science ®Google Scholar
• Carrasquilla G, Baron C, Monsell EM et al. Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether–lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg.86(1), 75–83 (2012).
   PubMed Web of Science ®Google Scholar
• Falade C, Manyando C. Safety profile of Coartem: the evidence base. Malar. J.8(Suppl. 1), S6 (2009).
   PubMedGoogle Scholar
• Adjei GO, Kurtzhals JA, Rodrigues OP et al. Amodiaquine-artesunate vs artemether–lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar. J.7, 127 (2008).
   PubMed Web of Science ®Google Scholar
• Maiteki-Sebuguzi C, Jagannathan P, Yau VM et al. Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children. Malar. J.7, 106 (2008).
   PubMedGoogle Scholar
• Coartem ® Dispersible international package leaflet. Novartis Pharma AG, Basel, Switzerland (2009).
   Google Scholar
• Bassat Q, Gonzalez R, Machevo S et al. Similar efficacy and safety of artemether–lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges. Malar. J.10(1), 369 (2011).
   PubMedGoogle Scholar
• Dellicour S, Hall S, Chandramohan D, Greenwood B. The safety of artemisinins during pregnancy: a pressing question. Malar. J.6, 15 (2007).
   PubMed Web of Science ®Google Scholar
• Sowunmi A, Oduola AM, Ogundahunsi OA et al. Randomised trial of artemether versus artemether and mefloquine for the treatment of chloroquine/sufadoxine-pyrimethamine-resistant falciparum malaria during pregnancy. J. Obstet. Gynaecol.18(4), 322–327 (1998).
   PubMedGoogle Scholar
• Adam I, Elwasila E, Mohammed Ali DA, Elansari E, Elbashir MI. Artemether in the treatment of falciparum malaria during pregnancy in eastern Sudan. Trans. R. Soc. Trop. Med. Hyg.98(9), 509–513 (2004).
   PubMed Web of Science ®Google Scholar
• Wang TY. Follow-up observation on the therapeutic effects and remote reactions of artemisinin (Qinghaosu) and artemether in treating malaria in pregnant woman. J. Tradit. Chin. Med.9(1), 28–30 (1989).
   PubMedGoogle Scholar
• Manyando C, Mkandawire R, Puma L et al. Safety of artemether–lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia. Malar. J.9, 249 (2010).
   PubMed Web of Science ®Google Scholar
• Adam I, Elhassan EM, Omer EM, Abdulla MA, Mahgoub HM, Adam GK. Safety of artemisinins during early pregnancy, assessed in 62 Sudanese women. Ann. Trop. Med. Parasitol.103(3), 205–210 (2009).
   PubMed Web of Science ®Google Scholar
• McGready R, Stepniewska K, Lindegardh N et al. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Eur. J. Clin. Pharmacol.62(12), 1021–1031 (2006).
   PubMed Web of Science ®Google Scholar
• Piola P, Nabasumba C, Turyakira E et al. Efficacy and safety of artemether–lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. Lancet Infect. Dis.10(11), 762–769 (2010).
   PubMed Web of Science ®Google Scholar
• McGready R, Tan SO, Ashley EA et al. A randomised controlled trial of artemether–lumefantrine versus artesunate for uncomplicated Plasmodium falciparum treatment in pregnancy. PLoS Med.5(12), E253 (2008).
   PubMed Web of Science ®Google Scholar
• Kaye DK, Nshemerirwe R, Mutyaba TS, Ndeezi G. A randomized clinical trial comparing safety, clinical and parasitological response to artemether–lumefantrine and chlorproguanil-dapsone in treatment of uncomplicated malaria in pregnancy in Mulago hospital, Uganda. J. Infect. Dev. Ctries.2(2), 135–139 (2008).
   PubMed Web of Science ®Google Scholar
• Bassat Q. The use of artemether–lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria. PLoS Negl. Trop. Dis.5(12), E1325 (2011).
   PubMedGoogle Scholar
• Krudsood S, Tangpukdee N, Muangnoicharoen S et al. Clinical efficacy of chloroquine versus artemether–lumefantrine for Plasmodium vivax treatment in Thailand. Korean J. Parasitol.45(2), 111–114 (2007).
   PubMedGoogle Scholar
• Bassat Q. The use of artemether–lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria. PLoS Negl. Trop. Dis.5(12), E1325 (2011).
   PubMedGoogle Scholar
• WHO Prequalified Medicines List. WHO, Geneva, Switzerland (2010).
   Google Scholar
• Abdulla S, Amuri B, Kabanywanyi AM et al. Early clinical development of artemether–lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects. Malar. J.9, 253 (2010).
   PubMedGoogle Scholar
• Kurth F, Belard S, Adegnika AA, Gaye O, Kremsner PG, Ramharter M. Do paediatric drug formulations of artemisinin combination therapies improve the treatment of children with malaria?. A systematic review and meta-analysis. Lancet Infect. Dis.10(2), 125–132 (2010).
   PubMed Web of Science ®Google Scholar
• Larru B, Molyneux E, ter Kuile FO, Taylor T, Molyneux M, Terlouw DJ. Malaria in infants below six months of age: retrospective surveillance of hospital admission records in Blantyre, Malawi. Malar. J.8, 310 (2009).
   PubMed Web of Science ®Google Scholar
• Meremikwu M, Alao MJ, Gbadoe AD et al. Efficacy, safety and PK of artemether–lumefantrine dispersible tablet in the treatment of acute uncomplicated Plasmodium falciparum malaria in infants <5 kg body weight. Am. J. Trop. Med. Hyg.85(Suppl. 6), 387 (2011).
   Google Scholar
• Barnes KI, Durrheim DN, Little F et al. Effect of artemether–lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med.2(11), E330 (2005).
   PubMed Web of Science ®Google Scholar
• Zurovac D, Ndhlovu M, Sipilanyambe N et al. Paediatric malaria case-management with artemether–lumefantrine in Zambia: a repeat cross-sectional study. Malar. J.6, 31 (2007).
   PubMed Web of Science ®Google Scholar
• Chizema-Kawesha E, Mukonka VM, Mwanza M et al. Evidence of substantial nationwide reduction of malaria cases and deaths due to scale-up of malaria control activities in Zambia, 2001–2008. World Health Organization, Zambia 19–23 January 2009. Impact Evaluation Mission Report. WHO, Geneva, Switzerland (2009).
   Google Scholar
• WHO. Global Malaria Programme, June 2009. Deployment of artemether–lumefantrine with rapid diagnostic tests at community level, Raya Valley, Tigray, Ethiopia. WHO, Geneva, Switzerland (2009).
   Google Scholar
• WHO. Global report on antimalarial drug efficacy and drug resistance: 2000–2010. WHO, Geneva, Switzerland (2010).
   Google Scholar
• Denis MB, Tsuyuoka R, Lim P et al. Efficacy of artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop. Med. Int. Health11(12), 1800–1807 (2006).
   PubMed Web of Science ®Google Scholar
• Song J, Socheat D, Tan B et al. Randomized trials of artemisinin-piperaquine, dihydroartemisinin–piperaquine phosphate and artemether–lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area. Malar. J.10, 231 (2011).
   PubMed Web of Science ®Google Scholar
• WHO. Update on Artemisinin Resistance – September 2011. WHO, Geneva, Switzerland (2011).
   Google Scholar
• WHO. Global Plan for Artemisinin Resistance Containment (GPARC). WHO, Geneva, Switzerland (2011).
   Google Scholar
• Dondorp AM, Fairhurst RM, Slutsker L et al. The threat of artemisinin-resistant malaria. N. Engl. J. Med.365(12), 1073–1075 (2011).
   PubMed Web of Science ®Google Scholar
• Rahman MM, Dondorp AM, Day NP et al. Adherence and efficacy of supervised versus non-supervised treatment with artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial. Trans. R. Soc.Trop. Med. Hyg.102(9), 861–867 (2008).
   PubMed Web of Science ®Google Scholar
• Kabanywanyi AM, Lengeler C, Kasim P et al. Adherence to and acceptability of artemether–lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania. Malar. J.9, 48 (2010).
   PubMed Web of Science ®Google Scholar
• Fogg C, Bajunirwe F, Piola P et al. Adherence to a six-dose regimen of artemether–lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda. Am. J. Trop. Med. Hyg.71(5), 525–530 (2004).
   PubMed Web of Science ®Google Scholar
• Simba DO, Kakoko D, Tomson G et al. Adherence to artemether/lumefantrine treatment in children under real-life situations in rural Tanzania. Trans. R. Soc. Trop. Med. Hyg.106(1), 3–9 (2012).
   PubMedGoogle Scholar
• Mace KE, Mwandama D, Jafali J et al. Adherence to treatment with artemether–lumefantrine for uncomplicated malaria in rural Malawi. Clin. Infect. Dis.53(8), 772–779 (2011).
   PubMed Web of Science ®Google Scholar
• Barrington J, Wereko-Brobby O, Ward P, Mwafongo W, Kungulwe S. SMS for life: a pilot project to improve anti-malarial drug supply management in rural Tanzania using standard technology. Malar. J.9, 298 (2010).
   PubMed Web of Science ®Google Scholar
• Feachem RG, Phillips AA, Hwang J et al. Shrinking the malaria map: progress and prospects. Lancet376(9752), 1566–1578 (2010).
   PubMed Web of Science ®Google Scholar
• WHO Global Malaria Programme. Update on Artemisinin Resistance – September 2011. WHO, Geneva, Switzerland (2011).
   Google Scholar
• Stepniewska K, White NJ. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob. Agents Chemother.52(5), 1589–1596 (2008).
   PubMed Web of Science ®Google Scholar
• Tarning J, Lindegardh N, Annerberg A et al. Pitfalls in estimating piperaquine elimination. Antimicrob. Agents Chemother.49(12), 5127–5128 (2005).
   PubMedGoogle Scholar
• malERA Consultative Group on Drugs. A research agenda for malaria eradication: drugs. PLoS Med.8(1), e1000402 (2011).
   PubMed Web of Science ®Google Scholar
• Meister S, Plouffe DM, Kuhen KL et al. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science334(6061), 1372–1377 (2011).
   PubMed Web of Science ®Google Scholar
• Wu T, Nagle A, Kuhen K et al. Imidazolopiperazines: hit to lead optimization of new antimalarial agents. J. Med. Chem.54(14), 5116–5130 (2011).
   PubMed Web of Science ®Google Scholar
• Mabunda S, Aponte JJ, Tiago A, Alonso P. A country-wide malaria survey in Mozambique. II. Malaria attributable proportion of fever and establishment of malaria case definition in children across different epidemiological settings. Malar. J.8, 74 (2009).
   PubMed Web of Science ®Google Scholar
• Vafa M, Troye-Blomberg M, Anchang J, Garcia A, Migot-Nabias F. Multiplicity of Plasmodium falciparum infection in asymptomatic children in Senegal: relation to transmission, age and erythrocyte variants. Malar. J.7, 17 (2008).
   PubMedGoogle Scholar
• Dal-Bianco MP, Koster KB, Kombila UD et al. High prevalence of asymptomatic Plasmodium falciparum infection in Gabonese adults. Am. J. Trop. Med. Hyg.77(5), 939–942 (2007).
   PubMed Web of Science ®Google Scholar
• Dunyo S, Milligan P, Edwards T, Sutherland C, Targett G, Pinder M. Gametocytaemia after drug treatment of asymptomatic Plasmodium falciparum. PLoS Clin. Trials1(4), E20 (2006).
   PubMedGoogle Scholar
• Baliraine FN, Afrane YA, Amenya DA et al. High prevalence of asymptomatic Plasmodium falciparum infections in a highland area of western Kenya: a cohort study. J. Infect. Dis.200(1), 66–74 (2009).
   PubMedGoogle Scholar
• Ogutu B, Tiono AB, Makanga M et al. Treatment of asymptomatic carriers with artemether–lumefantrine: an opportunity to reduce the burden of malaria?. Malar. J.9, 30 (2010).
   PubMedGoogle Scholar
• Doumbia SO, Ndiaye D, Koita OA et al. Improving malaria control in West Africa: interruption of transmission as a paradigm shift. Acta Trop.121(3), 175–183 (2012).
   PubMedGoogle Scholar
• Kern SE, Tiono AB, Makanga M et al. Community screening and treatment of asymptomatic carriers of Plasmodium falciparum with artemether–lumefantrine to reduce malaria disease burden: a modelling and simulation analysis. Malar. J.10, 210 (2011).
   PubMedGoogle Scholar
• von SL, Greenwood BM. Mass administrations of antimalarial drugs. Trends Parasitol.19(10), 452–460 (2003).
   PubMedGoogle Scholar
• von SL, Walraven G, Milligan PJ et al. The effect of mass administration of sulfadoxine–pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Trans. R. Soc. Trop. Med. Hyg.97(2), 217–225 (2003).
   PubMedGoogle Scholar
• Zulueta J, Kafuko GW, Mccrae AW, Cullen JR, Pedrsen CK, Wasswa DF. A malaria eradication experiment in the highlands of Kigezi (Uganda). East Afr. Med. J.41, 102–120 (1964).
   PubMedGoogle Scholar
• Molineaux L, Gramiccia G. The Garki project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. WHO, Geneva, Switzerland (1980).
   Google Scholar
• Kaneko A, Taleo G, Kalkoa M, Yamar S, Kobayakawa T, Bjorkman A. Malaria eradication on islands. Lancet356(9241), 1560–1564 (2000).
   PubMed Web of Science ®Google Scholar